Last reviewed · How we verify
NCT05789147: TRANSFER
Transcutaneous Vagus Nerve Stimulation in Heart Failure
NA trial testing Active tVNS in Heart Failure With Preserved Ejection Fraction in 29 participants. Completed in 31 December 2024.
30 September 2024
Quick facts
| Lead sponsor | Istituti Clinici Scientifici Maugeri SpA |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 15 June 2020 |
| Primary completion | 30 September 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Active tVNS
- Sham tVNS
Conditions studied
- Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →
- Heart Failure With Midrange Ejection Fraction — all drugs for Heart Failure With Midrange Ejection Fraction →
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Who can join
Adults 18 to 70, any sex, with Heart Failure With Preserved Ejection Fraction or Heart Failure With Midrange Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several studies have shown that alterations in autonomic nervous system function are implicated in the onset and progression of numerous cardiovascular diseases. Direct stimulation of the vagus nerve by means of a sleeve placed around the vagus nerve represents one of the methodologies proposed in the field of neuromodulation. This study, which is proposed as a pilot study for further application of the method in subjects with cardiovascular disease aims to verify and consolidate evidence on cardiovascular autonomic effects in patients with heart failure. Vagal stimulation will be achieved noninvasively by applying an external stimulator to the auricular site.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Impact of optimized transcutaneous auricular vagus nerve stimulation on cardiac autonomic profile in healthy subjects and heart failure patients.
Maestri R, Pinna GD, Robbi E, Cogliati C, et al · · 2024 · cited 7× · PMID 39016202 · DOI 10.1088/1361-6579/ad5ef6 -
Neuromodulation Therapies in Heart Failure: A State-of-the-Art Review.
Pahuja M, Akhtar KH, Krishan S, Nasir YM, et al · · 2023 · cited 5× · PMID 39131073 · DOI 10.1016/j.jscai.2023.101199 -
Treating heart failure by targeting the vagus nerve.
Gentile F, Orlando G, Montuoro S, Ferrari Chen YF, et al · · 2024 · cited 5× · PMID 39117958 · DOI 10.1007/s10741-024-10430-w -
The mechanism and clinical research of vagus nerve electrical stimulation in the treatment of myocardial ischemia-reperfusion injury.
Wang H, Zhang X, Li X, Xing J, et al · · 2026 · PMID 41716993 · DOI 10.1016/j.isci.2026.114657
Verify or expand the search:
- PubMed search for NCT05789147
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active tVNS
Trials testing the same drug.
- NCT06355388 — TRAnscutaneous vaGUS Nerve Stimulation in Patients With Chronic Heart Failure · NA · not yet recruiting
- NCT04396249 — tVNS for Cognitive Impairments in Community-Dwelling Elderly · NA · unknown
Other recruiting trials for Heart Failure With Preserved Ejection Fraction
Currently open trials in the same condition.
- NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
- NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
- NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
- NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
- NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting
Other Istituti Clinici Scientifici Maugeri SpA trials
Trials by the same sponsor.
- NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
- NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05789147 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05789147.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing